NCT05351554: A reported trial by Kinevant Sciences GmbH
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05351554 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 23, 2022 |
| Completion date | Nov. 15, 2022 |
| Required reporting date | Nov. 15, 2025, midnight |
| Actual reporting date | Feb. 18, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |